Glenmark Secures China Approval for RYALTRIS, Reinforcing Respiratory Innovation Leadership
Glenmark Pharmaceuticals Ltd. announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS® Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children. This approval is a significant milestone in Glenmark’s respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions. RYALTRIS® is a first-of-its-kind fixed-dose combination nasal spray that brings together an olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) to treat the symptoms of allergic rhinitis. It is Glenmark’s first globally commercialized branded specialty product and is already approved in several countries. Commercialization in China will be undertaken by Grand Pharmaceuticals Group Limited under an exclusive licensing agreement.
Key Highlights
- Glenmark Pharmaceuticals Ltd. secures approval from the National Medical Products Administration (NMPA) of China for RYALTRIS® Compound Nasal Spray for the treatment of Allergic Rhinitis (AR) in adults and children.
- RYALTRIS® is a first-of-its-kind fixed-dose combination nasal spray that brings together an olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) to treat the symptoms of allergic rhinitis.
- RYALTRIS® is Glenmark’s first globally commercialized branded specialty product and is already approved in several countries.
- Commercialization in China will be undertaken by Grand Pharmaceuticals Group Limited under an exclusive licensing agreement.
- The approval is a significant milestone in Glenmark’s respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions.